Cargando…

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma

[Image: see text] BTK is a member of the TEC family of non-receptor tyrosine kinases whose deregulation has been implicated in a variety of B-cell-related diseases. We have used structure-based drug design in conjunction with kinome profiling and cellular assays to develop a potent, selective, and i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Hong, Wang, Wenchao, Liu, Feiyang, Weisberg, Ellen L., Tian, Bei, Chen, Yongfei, Li, Binhua, Wang, Aoli, Wang, Beilei, Zhao, Zheng, McMillin, Douglas W., Hu, Chen, Li, Hong, Wang, Jinhua, Liang, Yanke, Buhrlage, Sara J., Liang, Junting, Liu, Jing, Yang, Guang, Brown, Jennifer R., Treon, Steven P., Mitsiades, Constantine S., Griffin, James D., Liu, Qingsong, Gray, Nathanael S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2014
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027949/ https://www.ncbi.nlm.nih.gov/pubmed/24556163 http://dx.doi.org/10.1021/cb4008524

Ejemplares similares

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model
por: Wu, Hong, et al.
Publicado: (2017)

High-throughput approaches to discover novel immunomodulatory agents for cancer
por: McMillin, Douglas W., et al.
Publicado: (2012)

Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies
por: Mei, Husheng, et al.
Publicado: (2023)

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation
por: Wang, Aoli, et al.
Publicado: (2016)

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
por: Wu, Hong, et al.
Publicado: (2015)

Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia
por: Hu, Chen, et al.
Publicado: (2021)

The race to stymie BTK: zanu zings
por: Kapoor, Prashant, et al.
Publicado: (2020)

Repurposing of Kinase Inhibitors for Treatment of COVID-19
por: Weisberg, Ellen, et al.
Publicado: (2020)

Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells
por: Weisberg, Ellen, et al.
Publicado: (2013)

Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy
por: Hu, Chen, et al.
Publicado: (2023)

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020)

Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies
por: Liu, Xiaochuan, et al.
Publicado: (2016)

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances
por: Liu, Xiaochuan, et al.
Publicado: (2016)

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
por: Jiang, Zongru, et al.
Publicado: (2020)

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity
por: McMillin, Douglas W., et al.
Publicado: (2010)

Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation
por: McMillin, Douglas W., et al.
Publicado: (2011)

Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus
por: Wang, Junjie, et al.
Publicado: (2023)

An overview of kinase downregulators and recent advances in discovery approaches
por: Wang, Beilei, et al.
Publicado: (2021)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours
por: Liu, Juan, et al.
Publicado: (2022)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ
por: Reagan, Michaela R., et al.
Publicado: (2012)

Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development
por: Yu, Xin, et al.
Publicado: (2022)

Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)
por: Liu, Feiyang, et al.
Publicado: (2016)

Can Weather Influence the Prevalence of Acute-on-chronic Liver Failure?
por: McMillin, Matthew
Publicado: (2019)

Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor
por: Kim, Hyung-Gu, et al.
Publicado: (2014)

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
por: Hu, Chen, et al.
Publicado: (2017)

Triamcinoline acetonide (kenalog) in treatment of cases of hay fever and its effect on pituitary-adrenal axis.
por: McMillin, W. P.
Publicado: (1971)

Quality Improvement Innovation in a Maternal and Child Health Network: Negotiating Course Corrections in Mid-Implementation
por: McMillin, Stephen Edward
Publicado: (2020)

Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity
por: He, Hongbin, et al.
Publicado: (2018)

Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia
por: Weisberg, Ellen, et al.
Publicado: (2020)

Inhibition of the deubiquitinase USP10 induces degradation of SYK
por: Yang, Jing, et al.
Publicado: (2020)

STK16 regulates actin dynamics to control Golgi organization and cell cycle
por: Liu, Juanjuan, et al.
Publicado: (2017)

Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities
por: Hu, Chen, et al.
Publicado: (2022)

Pharmacological inhibiting STAT5 for the treatment of FLT3‐ITD‐positive acute myeloid leukemia with triciribine phosphate monohydrate
por: Wu, Hong, et al.
Publicado: (2023)

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor
por: Kim, Hyung-Gu, et al.
Publicado: (2013)

Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
por: Zain, Rula, et al.
Publicado: (2021)

The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations
por: Weisberg, Ellen, et al.
Publicado: (2020)

Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences
por: Wang, Aoli, et al.
Publicado: (2020)

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
por: Treon, Steven P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4h3jm3jsdq295i48dsukmvjm6t